期刊文献+

不同配比头孢噻肟钠/他唑巴坦钠的体外抗菌作用 被引量:6

In vitro antibacterial activities of different ratios from matching cefotaxime/tazobactam
下载PDF
导出
摘要 目的研究4种不同配比的头孢噻肟钠/他唑巴坦钠(CTX/TAZ)(2:1、4:1、6:1、8:1)及头孢噻肟钠(CTX)单剂对四川地区临床分离致病菌的体外抗菌作用。方法采用平皿二倍稀释法测定465株临床分离致病菌的最低抑菌浓度(MIC)。结果联合配伍可以使金黄色葡萄球菌(MRSA)、表皮葡萄球菌(MSSE和MRSE)、粪肠球菌、大肠埃希菌(产ESBLs)、铜绿假单胞菌、阴沟肠杆菌、肺炎克雷伯菌(产ESBLs)和鲍曼不动杆菌等从CTX单用的MIC50值128~>256mg·mL-1降至2~64mg.L-1,下降幅度达4~128倍。结论不同配比的CTX/TAZ均有强大的杀菌作用,明显优于CTX单剂。6:1的CTX/TAZ复方制剂为较合理的配方组合,具有进一步的研究开发价值。 OBJECTIVE To study the antibacterial activities of cefotaxime (CTX) and different ratios from matching cefotaxime/ tazobactam(CTX/TAZ) (2 : 1,4 : 1,6 : 1 ,8 : 1 ) against clinically isolated pathogenic bacteria from Sichuan area in vitro. METH- ODS Minimal inhibitory concentrations (MIC) were determined by use of agar dilution method on 465 clinically isolated pathogenic bacteria. RESULTS MICs0 of CTX/TAZ with different ratios against Staphylococcus anreus ( MRSA), Staphylococcus epidermidis (MSSE and MRSE) , Enterococcus faecalis, Escherichia coli (ESBLs ~ ) , Pseudomonas aeruginosa, Aerobacter cloacae, Klebsiella pneumoniae( ESBLs + ) and Baumanii were 2 -64 mg L-1 , which was 4 - 128 times lower than that of CTX alone. CONCLUSION Different formulas of CTX/TAZ (2 : 1,4 : 1,6 : 1, 8 : 1 ) showed higher antibacterial activity against most clinical isolates than CTX alone in vitro. CTX/TAZ 6 : 1 is a better formulation and valuable to be investigated.
出处 《华西药学杂志》 CAS CSCD 北大核心 2009年第1期38-41,共4页 West China Journal of Pharmaceutical Sciences
关键词 头孢噻肟钠/他唑巴坦钠 体外抗菌作用 Cefotaxime/Tazobactam (CTX/TAZ) In vitro antibacterial activity
  • 相关文献

参考文献7

二级参考文献25

  • 1房翔宇.CT检查与普放检查在肺部孤立性球形病变临床诊断中的应用[J].中西医结合心血管病电子杂志,2019,0(36):115-115. 被引量:5
  • 2林新中.一种新的β-内酰胺酶抑制剂──他佐巴坦[J].中国医院药学杂志,1995,15(10):467-468. 被引量:4
  • 3[1]Rotschafe JC,Ostergaas BE.Combination β-lactam and lacta mase-inhibitor products:amimic-robial activity and efficiency of enzyme inhibition[J].Am J Heatth-Syst Pharm,1995,52:15-23.
  • 4[3]Lister PD,Prevan AM,Sanden CC.Importance of beta-lactamase inhibitor phamacokinetics in the phamavodynamies of inhivitordrug combinations:studies with piperaeillin-tazobactam and piperacillin-sulbactam[J].Antimic Agents Chemother,1997,41:721-727.
  • 5[4]National Committee for Clinical Labarotory Stanch.Performance standards for antimicrobial susceptibility testing ninth informational supplement[M].NCCLS documents,2000.17-99.
  • 6National Committee for Clinical Laboratory Standard, 2002. Performance Standards for Antimicrobial Susceptibility Testing. NCCLS, Wayne, Pa.
  • 7Rhomberg PR, Jones RN , MYSTIC Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials:report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis, 2003,47:365-372.
  • 8Pfaller MA, Jones RN , MYSTIC Study Group. Antimicrobial susceptibility of inducible Amp C β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents, 2002,19:383-388.
  • 9Sader HS, Biedenbach DJ ,Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis, 2003,47:361-364.
  • 10Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and resistance patterns in Brazilian hospitals:summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, 2001,5:200-214.

共引文献372

同被引文献40

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部